about
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivoArresting serotoninThe analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulationDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersAripiprazole: from pharmacological profile to clinical useTargeting G protein coupled receptor-related pathways as emerging molecular therapiesMismatch negativity: translating the potentialDopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?DREADDs: novel tools for drug discovery and developmentPositive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medicationsUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismLigand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-targetUnique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in RatsCrosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integrationLabel-free integrative pharmacology on-target of opioid ligands at the opioid receptor familyA simple method for quantifying functional selectivity and agonist biasEffects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality DisorderSKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase CInvestigation of D₂ receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling.Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in ratsDuplexed label-free G protein--coupled receptor assays for high-throughput screening.Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity.The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacyDiscovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptorβ-Adrenergic receptor subtype signaling in heart: from bench to bedside.Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor.Teaching old receptors new tricks: biasing seven-transmembrane receptors.Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disordersPharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic painDiscovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization propertiesDiscovery of regulators of receptor internalization with high-throughput flow cytometry.Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivoThe potential for selective pharmacological therapies through biased receptor signalingIdentification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.Label-Free Receptor Assays.PharmGKB summary: dopamine receptor D2
P2860
Q24322122-06538BBA-552D-4472-B0DC-DFEAB1325DE8Q24647492-D85938D2-5C72-4B05-8522-853F56A9DD2EQ24648701-4C487228-3516-48D2-853B-6BAE5F4DCCC5Q26748728-9689EFD3-695B-488D-8AF1-B591EF3F0516Q26778312-C241937C-56E5-4CAC-A9C5-1091B32A6356Q26829964-964A0FB7-51A7-4518-B464-F36C7FC0EBC5Q26830827-590571C3-499B-430E-9886-CF87B28496BDQ26864383-B19E4914-57E6-482F-8204-63C70E79CF7CQ26995396-73E8D6F0-B4F2-4A06-AEE2-C469610039C1Q27027736-A3AB7D90-2F0D-465C-9567-C231DD9888A2Q28084069-C4979BF1-9CE7-444C-92E7-37ECCB4AA3CDQ28477403-07D901A2-9932-405E-B0EE-7F12B56D5518Q28546441-6195AD7B-D88C-4625-B622-42D1EB92BE6BQ28564967-7D48D95F-B6E4-43A5-AEE8-91648F77F09AQ28709650-009D946E-F53E-4AFA-8BC2-C122291AA3C2Q28728741-E137CAEF-526F-42E2-B38E-40B2EE7CD17BQ29038503-6B6A944C-2842-40E8-9BD7-EBF86E4FC576Q30400003-BB1701C4-0038-42F9-9635-67BD16A5696DQ30412744-F638D3CC-0D6C-4CF4-9911-CE1AD6E8B88AQ30480298-9DC5B98F-5890-4AE4-A9DD-3554E4E1B398Q30581703-5E0A809E-41C7-4CD4-BF1F-73B97AE89038Q33386660-D7809909-AC3F-40E0-9B40-C56444F1146BQ33697312-26D8428A-F4B4-47B1-BDAD-0BC69D465E4EQ33714695-35DFF299-AC09-45A8-A944-E361D57920F8Q33714922-9E1C0A4B-4573-4066-A747-7E264819B69BQ33742774-8FBFAA4E-593A-4DDD-924F-59B5E568F83EQ33828730-2657B9DD-D1A5-4CB6-9171-593B7FF83A15Q33888491-E3199D08-EC65-41B6-B25B-9BD7847F838DQ33985759-F8069B73-12C6-4C64-8D6A-BD6AFCCA2755Q34011162-FBF04548-4A75-40FE-BD81-AD53F0D3725EQ34050607-25E889D6-0E49-47BE-918E-DEE18E34747FQ34118976-CF3A36C2-1276-4352-8D46-417DDE391B0EQ34227284-EA6E7CDB-AA0C-4377-9F51-1CC1900606DAQ34244869-5F81A930-F5A7-49B3-B056-DDA6849B33D4Q34327895-F1E2B9D8-1354-485A-B94D-0D78AB47EF69Q34402623-3E59211A-ECD7-4177-B875-BC7E49A0A2A0Q34402658-80BB59A1-727E-4D34-B2D5-A390E240CAB9Q34461713-BC4AD26A-18D2-476D-8135-2DC27A91E884Q34473007-72281796-7B48-4B31-9BD0-C257DA0A62EFQ34970259-66E5628D-3017-48C9-AC14-EFF25AC8AB2A
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
GPCR functional selectivity has therapeutic impact.
@en
type
label
GPCR functional selectivity has therapeutic impact.
@en
prefLabel
GPCR functional selectivity has therapeutic impact.
@en
P2860
P1476
GPCR functional selectivity has therapeutic impact.
@en
P2093
Richard B Mailman
P2860
P304
P356
10.1016/J.TIPS.2007.06.002
P577
2007-07-13T00:00:00Z